Circ Heart Fail :美国供体肥胖可能不会影响心脏移植的结果

2020-09-20 心关注 心关注

一项研究表明,与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。

近日发表在《循环·心力衰竭》(Circulation: Heart Failure)杂志的一项研究表明,与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长,这些发现可能支持将肥胖和心脏较大的捐赠者纳入已经非常低的捐赠者库中。

研究人员分析了2003年至2017年器官共享联合网络数据库中首次进行的26,532例单器官心脏移植手术,其中,3.5%的移植器官来自BMI至少为40 kg/m2的供体,并评估了供体的严重肥胖与受体的短期疗效和1年生存率之间的关系。

供体特征

在有严重肥胖的供体移植中,67.4%的移植体与受体大小不匹配,而在没有严重肥胖的供体中,这一比例为9.8%(P<0.01)。大小不匹配的供体体重超过受体体重的130%。此外,与没有严重肥胖的捐献者相比,严重肥胖的捐赠者更容易患糖尿病(10.4% vs. 3.1%;P<0.01)和高血压(33.3% vs. 14.8%,P<0.01)。

对短期、1年预后的影响

在一项单变量分析中,研究人员对患有严重肥胖的捐献者与无肥胖捐献者的心脏移植结果进行了比较,结果发现两组之间在以下结果上没有显着差异:

急性排斥反应(无严重肥胖 1.8%;重度肥胖 1.5%;P=0.54);术后透析(无重度肥胖 10%;重度肥胖 9.4%;P=0.53);需要起搏器(无严重肥胖 3.3%;重度肥胖 3.8%;P=0.34);术后卒中(无重度肥胖 2.4%;重度肥胖 3.4%;P=0.07);1年死亡率(无重度肥胖 11.2%;重度肥胖 11.3%;P=0.9);1年时移植物衰竭(无严重肥胖 3.3%,重度肥胖 2.8%;P=0.37);动脉粥样硬化引起的移植物衰竭(两组均为1.7%;P=0.85)。

经过风险调整后,供体严重肥胖与受体长期存活率较低无关(HR=0.928;95%CI 0.805-1.069)。

研究作者表示,这项研究表明,经过仔细选择,肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。鉴于美国肥胖症的发生率持续增加,这项研究有可能通过增加捐赠者的数量和改善日益增多的终末期心力衰竭患者的预后来扩大极低的捐赠者群体。

原始出处:

Elizabeth D Krebs, Jared P Beller, J Hunter Mehaffey,et al. How Big Is Too Big?: Donor Severe Obesity and Heart Transplant Outcomes.Circ Heart Fail. 2020 Sep 16;CIRCHEARTFAILURE119006688. doi: 10.1161/CIRCHEARTFAILURE.119.006688.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2021-01-09 feather85
  2. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-25 咻凡

    与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-24 Lexi

    肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-22 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-22 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-20 ms6000000417346414

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-20 ms2000001921731409

    🧱

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-20 ms2000000921612050

    学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1631886, encodeId=8e78163188621, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Sat Jan 09 00:06:09 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888228, encodeId=6067888228a7, content=与接受非重度肥胖供体心脏移植的患者相比,接受重度肥胖供体心脏移植的患者没有发生更多的不良事件,且1年生存率也差不多。随着肥胖症患病率的逐渐上升,潜在肥胖的器官捐赠者比例可能会继续增长。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Sep 25 11:37:01 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887943, encodeId=a32188e94301, content=肥胖捐赠者的心脏可以在不增加受体风险的情况下使用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Thu Sep 24 14:12:06 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357602, encodeId=5acb135e602f0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563370, encodeId=e4b615633e028, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Sep 22 02:06:09 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886914, encodeId=417e8869142c, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200920/26ffe09b2ec349a5b0e885725301feb4/d8fd6c3128674fa7b07e3f152d141e84.jpg, createdBy=3d685419908, createdName=ms6000000417346414, createdTime=Sun Sep 20 19:05:32 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886831, encodeId=e1508868317e, content=🧱, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34c5419838, createdName=ms2000001921731409, createdTime=Sun Sep 20 12:01:14 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886823, encodeId=149a88682320, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2115419824, createdName=ms2000000921612050, createdTime=Sun Sep 20 11:15:40 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886820, encodeId=c57488682079, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded52568391, createdName=笑西风2019, createdTime=Sun Sep 20 11:14:41 CST 2020, time=2020-09-20, status=1, ipAttribution=)]
    2020-09-20 笑西风2019

    厉害

    0

相关资讯

Nature Metabolism:不健康的生活方式正在成为癌症的“推手”!

多种流行病学数据都清楚地表明,不健康的生活方式是最常见癌症的最强决定因素,并占所有癌症和癌症相关死亡人数的35%-50%。

Eur Respir J:肥胖和正常体重哮喘患者哮喘药物分析

尽管FEV1较低且FEV1/FVC%较低,肥胖的哮喘患者使用的哮喘药物种类和ICS剂量均高于正常体重的哮喘患者。需要更好地了解导致药物使用增加的因素,以改善哮喘亚组的预后。

Am J Clin Nutr:摄入脱脂牛奶并不会比全脂牛奶更能降低儿童过度肥胖的风险

在北美,大多数儿童每天饮用牛奶。建议2岁以上的儿童食用减脂(0.1-2%)的牛乳,以降低肥胖的风险。本研究旨在评估1-18岁儿童牛乳脂肪摄入量与脂肪率的关系。

Scand J Med Sci Sports:活动视频游戏可用于降低儿童和青少年的肥胖风险

本研究旨在调查活动视频游戏(AVG)对儿童和青少年肥胖和身体活动水平的效果。

GUT:脂肪组织来源的细菌与肥胖症和2型糖尿病的发病相关

肥胖患病率在过去几十年中以惊人的速度增长,据估计,全球超过44%人口超重,超过3亿人受到病态肥胖的影响。肥胖是多种疾病共存的主要危险因素。

Obesity 2020:Plenity(Gelesis100)治疗肥胖疗效明显

GLOW是一项关键性研究,结果表明,接受Plenity(Gelesis100)治疗的成年人在试验期间平均体重下降了13.5%,参与者平均接受Plenity(Gelesis100)治疗60天。